Genetic variation in DROSHA 3′UTR regulated by hsa-miR-27b is associated with bladder cancer risk

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Yuan, Lin ^a,b   Chu, Haiyan ^b,c   Wang, Meilin ^b,c   Gu, Xiaojian ^a   Shi, Danni ^b   Lan, Ma ^b   Zhong, Dongyan ^b   Du, Mulong ^b   Li, Pu ^b   Tong, Na ^c   Fu, Guangbo ^b   Qin, Chao ^b   Yin, Changjun ^b   Zhang, Zhengdong ^b,c  

^a AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Nanjing Medical University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DICER; DROSHA; HSA MIR 27B; MICRORNA; RIBONUCLEASE III; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; DEAD BOX PROTEIN; DICER1 PROTEIN, HUMAN; DROSHA PROTEIN, HUMAN; MIRN27 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BINDING SITE; BLADDER CANCER; CANCER RISK; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DICER GENE; DROSHA GENE; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; ASIAN CONTINENTAL ANCESTRY GROUP; BLADDER TUMOR; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED;

3' UNTRANSLATED REGIONS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; BINDING SITES; CASE-CONTROL STUDIES; DEAD-BOX RNA HELICASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBONUCLEASE III; URINARY BLADDER NEOPLASMS;

EID: 84896717937     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081524     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30. doi:10.3322/caac.21166. PubMed: 23335087.
2. Han S, Zhang S, Chen W, Li C (2013) Analysis of the status and trends of bladder cancer incidence in China. Oncology Process 11: 89-95.
3. Kiriluk KJ, Prasad SM, Patel AR, Steinberg GD, Smith ND (2012) Bladder cancer risk from occupational and environmental exposures. Urol Oncol 30: 199-211. doi:10.1016/j.urolonc.2011.10.010. PubMed: 22385990.
4. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S et al. (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63: 8108-8112. PubMed: 14678961. (Pubitemid 37549454)
5. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boevé ER et al. (2004) FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64: 1911-1914. doi:10.1158/0008-5472.CAN-03-2421. PubMed: 15026322. (Pubitemid 38339432)
6. Lamy A, Gobet F, Laurent M, Blanchard F, Varin C et al. (2006) Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 176: 2686-2689. doi:10.1016/j.juro. 2006.07.132. PubMed: 17085196.
7. Kiemeney LA, Thorlacius S, Sulem P, Geller F, Aben KK et al. (2008) Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 40: 1307-1312. doi:10.1038/ng.229. PubMed: 18794855.
8. Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T et al. (2009) Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 41: 991-995. doi: 10.1038/ng.421. PubMed: 19648920.
9. Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A et al. (2010) A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 42: 415-419. doi:10.1038/ng.558.PubMed: 20348956.
10. Rafnar T, Vermeulen SH, Sulem P, Thorleifsson G, Aben KK et al. (2011) European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet 20: 4268-4281. doi:10.1093/hmg/ddr303. PubMed: 21750109.
11. Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Malats N et al. (2011) A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet 20: 4282-4289. doi: 10.1093/hmg/ddr342. PubMed: 21824976.
12. Tang W, Fu YP, Figueroa JD, Malats N, Garcia-Closas M et al. (2012) Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer. Hum Mol Genet 21: 1918-1930. doi:10.1093/hmg/ddr619. PubMed: 22228101.
13. Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N et al. (2005) Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 309: 1573-1576. doi:10.1126/science.1115079. PubMed: 16081698. (Pubitemid 41266485)
14. Blaszczyk J, Tropea JE, Bubunenko M, Routzahn KM, Waugh DS et al. (2001) Crystallographic and modeling studies of RNase III suggest a mechanism for double-stranded RNA cleavage. Structure 9: 1225-1236. doi:10.1016/S0969-2126(01) 00685-2. PubMed: 11738048. (Pubitemid 34025056)
15. Lee Y, Kim M, Han J, Yeom KH, Lee S et al. (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23: 4051-4060. doi: 10.1038/sj.emboj.7600385. PubMed: 15372072. (Pubitemid 39472426)
16. Liu X, Fortin K, Mourelatos Z (2008) MicroRNAs: biogenesis and molecular functions. Brain Pathol 18: 113-121. doi:10.1111/j.1750-3639.2007.00121.x. PubMed: 18226106.
17. Carthew RW (2006) Gene regulation by microRNAs. Curr Opin Genet Dev 16: 203-208. doi:10.1016/j.gde.2006.02.012. PubMed: 16503132.
18. Chen CZ (2005) MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353: 1768-1771. doi:10.1056/NEJMp058190. PubMed: 16251533.
19. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D et al. (2007) A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A 104: 13513-13518. doi:10.1073/pnas.0706217104. PubMed: 17686970. (Pubitemid 47293976)
20. Xiong F, Wu C, Chang J, Yu D, Xu B et al. (2011) Genetic variation in an miRNA-1827 binding site in MYCL1 alters susceptibility to small-cell lung cancer. Cancer Res 71: 5175-5181. doi: 10.1158/0008-5472.CAN-10-4407. PubMed: 21676885.
21. Catto JW, Miah S, Owen HC, Bryant H, Myers K et al. (2009) Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 69: 8472-8481. doi:10.1158/0008-5472.CAN-09-0744. PubMed: 19843843.
22. Tao J, Wu D, Li P, Xu B, Lu Q et al. (2012) microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer T24 cells. Mol Med Rep 5: 167-172. PubMed: 21935572.
23. Wu D, Tao J, Xu B, Li P, Lu Q et al. (2012) Downregulation of Dicer, a component of the microRNA machinery, in bladder cancer. Mol Med Rep 5: 695-699. PubMed: 22179432.
24. Han Y, Liu Y, Gui Y, Cai Z (2013) Inducing cell proliferation inhibition and apoptosis via silencing Dicer, Drosha, and Exportin 5 in urothelial carcinoma of the bladder. J Surg Oncol 107: 201-205. doi:10.1002/jso.23214. PubMed: 22766726.
25. Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG et al. (2010) Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 31: 1805-1812. doi:10.1093/carcin/bgq168. PubMed: 20732906.
26. Horikawa Y, Wood CG, Yang H, Zhao H, Ye Y et al. (2008) Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res 14: 7956-7962. doi: 10.1158/1078-0432.CCR-08-1199. PubMed: 19047128.
27. Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB et al. (2008) Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res 68: 2530-2537. doi: 10.1158/0008-5472.CAN-07-5991. PubMed: 18381463. (Pubitemid 351521830)
28. Qin Y, Xia Y, Wu W, Han X, Lu C et al. (2012) Genetic variants in microRNA biogenesis pathway genes are associated with semen quality in a Han-Chinese population. Reprod Biomed Online.
29. Wang M, Wang M, Yuan L, Wu D, Zhang Z et al. (2010) A novel XPF -357A>C polymorphism predicts risk and recurrence of bladder cancer. Oncogene 29: 1920-1928. doi:10.1038/onc.2009.484. PubMed: 20062074.
30. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265. doi:10.1093/bioinformatics/bth457. PubMed: 15297300. (Pubitemid 40202029)
31. Lee Y, Ahn C, Han J, Choi H, Kim J et al. (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature 425: 415-419. doi: 10.1038/nature01957. PubMed: 14508493. (Pubitemid 37187272)
32. Sung H, Lee KM, Choi JY, Han S, Lee JY et al. (2011) Common genetic polymorphisms of microRNA biogenesis pathway genes and risk of breast cancer: a case-control study in Korea. Breast Cancer Res Treat 130: 939-951. doi:10.1007/s10549-011-1656-2. PubMed: 21766210.
33. Weng Y, Chen Y, Chen J, Liu Y, Bao T (2013) Common genetic variants in the microRNA biogenesis pathway are associated with malignant peripheral nerve sheath tumor risk in a Chinese population. Cancer. Epidemiol.
34. Wu X, Ros MM, Gu J, Kiemeney L (2008) Epidemiology and genetic susceptibility to bladder cancer. BJU Int 102: 1207-1215. doi:10.1111/j.1464- 410X.2008.07961.x. PubMed: 19035883.
35. Chu H, Wang M, Zhang Z (2013) Bladder cancer epidemiology and genetic susceptibility. J Biomed Res 27: 170-178. doi:10.7555/JBR.27.20130026. PubMed: 23720672.
36. Sugito N, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A et al. (2006) RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res 12: 7322-7328. doi: 10.1158/1078-0432.CCR-06-0515. PubMed: 17121874. (Pubitemid 46095404)
37. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA et al. (2008) Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359: 2641-2650. doi:10.1056/NEJMoa0803785. PubMed: 19092150.
38. Dedes KJ, Natrajan R, Lambros MB, Geyer FC, Lopez-Garcia MA et al. (2011) Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer 47: 138-150. doi:10.1016/j.ejca.2010.08.007. PubMed: 20832293.
39. Scotto L, Narayan G, Nandula SV, Subramaniyam S, Kaufmann AM et al. (2008) Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. Mol Cancer 7: 58. doi:10.1186/1476-4598-7-58. PubMed: 18559093.
40. Ye J, Wu X, Wu D, Wu P, Ni C et al. (2013) miRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer. PLOS ONE 8: e60687. doi:10.1371/journal.pone.0060687. PubMed: 23593282.
41. Lee JJ, Drakaki A, Iliopoulos D, Struhl K (2012) MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene.